ImmuCell Corp
NASDAQ:ICCC
Intrinsic Value
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. [ Read More ]
The intrinsic value of one ICCC stock under the Base Case scenario is 7.87 USD. Compared to the current market price of 5.3 USD, ImmuCell Corp is Undervalued by 33%.
Valuation Backtest
ImmuCell Corp
Run backtest to discover the historical profit from buying and selling ICCC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of ImmuCell Corp's business.
What risks and challenges
does ImmuCell Corp face in the near future?
Summarize the latest earnings report
of ImmuCell Corp.
Provide P/E
for ImmuCell Corp and its competitors.
Balance Sheet Decomposition
ImmuCell Corp
Current Assets | 12m |
Cash & Short-Term Investments | 2m |
Receivables | 2m |
Other Current Assets | 8m |
Non-Current Assets | 32.6m |
PP&E | 32.4m |
Intangibles | 140k |
Other Non-Current Assets | 80k |
Current Liabilities | 3.3m |
Accounts Payable | 780k |
Accrued Liabilities | 930k |
Other Current Liabilities | 1.6m |
Non-Current Liabilities | 15.2m |
Long-Term Debt | 10.9m |
Other Non-Current Liabilities | 4.3m |
Earnings Waterfall
ImmuCell Corp
Revenue
|
17.5m
USD
|
Cost of Revenue
|
-13.6m
USD
|
Gross Profit
|
3.9m
USD
|
Operating Expenses
|
-9.6m
USD
|
Operating Income
|
-5.7m
USD
|
Other Expenses
|
-27k
USD
|
Net Income
|
-5.8m
USD
|
Free Cash Flow Analysis
ImmuCell Corp
What is Free Cash Flow?
ICCC Profitability Score
Profitability Due Diligence
ImmuCell Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
ImmuCell Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ICCC Solvency Score
Solvency Due Diligence
ImmuCell Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
ImmuCell Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ICCC Price Targets Summary
ImmuCell Corp
According to Wall Street analysts, the average 1-year price target for ICCC is 14 USD .
Ownership
ICCC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ICCC Price
ImmuCell Corp
Average Annual Return | 3.35% |
Standard Deviation of Annual Returns | 28% |
Max Drawdown | -63% |
Market Capitalization | 41.1m USD |
Shares Outstanding | 7 750 860 |
Percentage of Shares Shorted | 0.1% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
Contact
IPO
Employees
Officers
The intrinsic value of one ICCC stock under the Base Case scenario is 7.87 USD.
Compared to the current market price of 5.3 USD, ImmuCell Corp is Undervalued by 33%.